It depends on your risk tolerance: conservative investors should rotate to Merck, while high-conviction traders should wait for the full Phase 3 dataset.

Moderna’s 14% pop reflects a short-covering squeeze and repricing of pipeline optionality following Wolfe Research’s upgrade to Peer Perform. However, holding at $158+ requires high conviction: the $9.2B peak sales figure is an unadjusted wall-street model assumption across multiple indications—not active product orders—and must be split 50/50 with partner Merck. Furthermore, Moderna's trailing twelve-month revenue has declined 27.6% to $2.23B, and detailed numerical Phase 3 INTerpath-001 data (including overall survival and hazard ratios) has not yet been peer-reviewed or fully presented.